Evan Lockwood Rachlin, Director at Iambic Therapeutics, Inc. (IAM), bought 718,750 shares at $16.00 ($11.5M) on 2026-10-16, disclosed to the SEC on 2026-10-19.
Iambic Therapeutics Director Evan Lockwood Rachlin purchased $11.5 million of stock at $16.00, marking the largest insider purchase in the company's history. This significant accumulation suggests high conviction in the company's near-term prospects.
The stock is currently trading at $16.00, which is 100% below its 52-week high of $32.00, representing a substantial discount to recent highs.
Insider purchased $11.5M, the largest ever in company history; track this momentum.
Insufficient data — needs manual review
Nothing distinguishes this filing.